Valeant Pharmaceuticals

Valeant Pharmaceuticals International is an international pharmaceutical company headquartered in Laval, Quebec near Montreal ( Canada). Valeant is traded on the Toronto Stock Exchange ( TSX) and the New York Stock Exchange ( NYSE) under each symbol " VRX ". It researches, develops and manufactures pharmaceuticals and markets patented drugs, generic drugs and OTC medicines for the treatment of dermatological and ophthalmology.

The company was founded in 1960 and achieved in 2013 with 7,500 employees worldwide sales of approximately 5.8 billion U.S. dollars.

The Swedish pharmaceutical company Meda AB acquired in 2008 businesses of Valeant in Western and Eastern Europe for 392 million U.S. dollars. This exists, inter alia, no German subsidiary more. The former Valeant products are sold in Germany in the meantime by the MEDA Pharma Germany ( Bad Homburg ).

In 2010, Valeant merged with the Canadian pharmaceutical company Biovail also, name and registered office of the company Valeant were retained.

797543
de